161 related articles for article (PubMed ID: 31119047)
1. Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer.
Wang Y; Li X; Liu X; Chen Y; Yang C; Tan C; Wang B; Sun Y; Zhang X; Gao Y; Ding J; Meng L
Cancer Biol Med; 2019 Feb; 16(1):66-83. PubMed ID: 31119047
[TBL] [Abstract][Full Text] [Related]
2. Repressing MYC by targeting BET synergizes with selective inhibition of PI3Kα against B cell lymphoma.
Chen ZQ; Cao ZR; Wang Y; Zhang X; Xu L; Wang YX; Chen Y; Yang CH; Ding J; Meng LH
Cancer Lett; 2022 Jan; 524():206-218. PubMed ID: 34688842
[TBL] [Abstract][Full Text] [Related]
3. Decrease in phosphorylated ERK indicates the therapeutic efficacy of a clinical PI3Kα-selective inhibitor CYH33 in breast cancer.
Liu XL; Xu YC; Wang YX; Chen Y; Wang BB; Wang Y; Chen YH; Tan C; Hu LD; Ma QY; Zhang YC; Sun YM; Gao YL; Yang CH; Ding J; Meng LH
Cancer Lett; 2018 Oct; 433():273-282. PubMed ID: 30003928
[TBL] [Abstract][Full Text] [Related]
4. Intact regulation of G1/S transition renders esophageal squamous cell carcinoma sensitive to PI3Kα inhibitors.
Zhang X; Wang Y; Zhang X; Shen Y; Yang K; Ma Q; Qiao Y; Shi J; Wang Y; Xu L; Yang B; Ge G; Hu L; Kong X; Yang C; Chen Y; Ding J; Meng L
Signal Transduct Target Ther; 2023 Apr; 8(1):153. PubMed ID: 37041169
[TBL] [Abstract][Full Text] [Related]
5. PI3Kα inhibitor CYH33 triggers antitumor immunity in murine breast cancer by activating CD8
Sun P; Zhang X; Wang RJ; Ma QY; Xu L; Wang Y; Liao HP; Wang HL; Hu LD; Kong X; Ding J; Meng LH
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34373258
[TBL] [Abstract][Full Text] [Related]
6. PI3Kα inhibitors sensitize esophageal squamous cell carcinoma to radiation by abrogating survival signals in tumor cells and tumor microenvironment.
Shi JJ; Xing H; Wang YX; Zhang X; Zhan QM; Geng MY; Ding J; Meng LH
Cancer Lett; 2019 Sep; 459():145-155. PubMed ID: 31173854
[TBL] [Abstract][Full Text] [Related]
7. Genome-wide gain-of-function screening identifies EZH2 mediating resistance to PI3Kα inhibitors in oesophageal squamous cell carcinoma.
Xing H; Gao M; Wang Y; Zhang X; Shi J; Wang X; Liu X; Ma Q; Kong X; Yang C; Ding J; Meng L
Clin Transl Med; 2022 May; 12(5):e835. PubMed ID: 35604910
[TBL] [Abstract][Full Text] [Related]
8. A CDK4/6 inhibitor enhances cytotoxicity of paclitaxel in lung adenocarcinoma cells harboring mutant KRAS as well as wild-type KRAS.
Zhang XH; Cheng Y; Shin JY; Kim JO; Oh JE; Kang JH
Cancer Biol Ther; 2013 Jul; 14(7):597-605. PubMed ID: 23792647
[TBL] [Abstract][Full Text] [Related]
9. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
10. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
[TBL] [Abstract][Full Text] [Related]
11. Adaptive resistance to PI3Kα-selective inhibitor CYH33 is mediated by genomic and transcriptomic alterations in ESCC cells.
Wang YX; Zhang X; Ma QY; Hu LD; Zhang X; Wang Y; Xu L; Yang CH; Tan C; Kong XY; Ding J; Meng LH
Cell Death Dis; 2021 Jan; 12(1):85. PubMed ID: 33446653
[TBL] [Abstract][Full Text] [Related]
12. BYL719, a selective inhibitor of phosphoinositide 3-Kinase α, enhances the effect of selumetinib (AZD6244, ARRY-142886) in KRAS-mutant non-small cell lung cancer.
Ku BM; Jho EH; Bae YH; Sun JM; Ahn JS; Park K; Ahn MJ
Invest New Drugs; 2015 Feb; 33(1):12-21. PubMed ID: 25342139
[TBL] [Abstract][Full Text] [Related]
13. p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells.
Cen L; Carlson BL; Schroeder MA; Ostrem JL; Kitange GJ; Mladek AC; Fink SR; Decker PA; Wu W; Kim JS; Waldman T; Jenkins RB; Sarkaria JN
Neuro Oncol; 2012 Jul; 14(7):870-81. PubMed ID: 22711607
[TBL] [Abstract][Full Text] [Related]
14. Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations.
Jiang ZB; Huang J; Xie C; Li X; Liu L; He J; Pan H; Huang L; Fan XX; Yao XJ; Xie Y; Li N; Liu L; He JX; Leung EL
Oncol Rep; 2016 Jul; 36(1):365-75. PubMed ID: 27121230
[TBL] [Abstract][Full Text] [Related]
15. Palbociclib, a selective CDK4/6 inhibitor, enhances the effect of selumetinib in RAS-driven non-small cell lung cancer.
Zhou J; Zhang S; Chen X; Zheng X; Yao Y; Lu G; Zhou J
Cancer Lett; 2017 Nov; 408():130-137. PubMed ID: 28866094
[TBL] [Abstract][Full Text] [Related]
16. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
17. Antitumor Activity of DFX117 by Dual Inhibition of c-Met and PI3Kα in Non-Small Cell Lung Cancer.
Fan Y; Ding H; Kim D; Bach DH; Hong JY; Xu Y; Lee SK
Cancers (Basel); 2019 May; 11(5):. PubMed ID: 31060329
[TBL] [Abstract][Full Text] [Related]
18. Combined inhibition of ACK1 and AKT shows potential toward targeted therapy against KRAS-mutant non-small-cell lung cancer.
Yu X; Liu J; Qiu H; Hao H; Zhu J; Peng S
Bosn J Basic Med Sci; 2021 Apr; 21(2):198-207. PubMed ID: 32530390
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models.
Lee MS; Helms TL; Feng N; Gay J; Chang QE; Tian F; Wu JY; Toniatti C; Heffernan TP; Powis G; Kwong LN; Kopetz S
Oncotarget; 2016 Jun; 7(26):39595-39608. PubMed ID: 27167191
[TBL] [Abstract][Full Text] [Related]
20. Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC.
Moro M; Caiola E; Ganzinelli M; Zulato E; Rulli E; Marabese M; Centonze G; Busico A; Pastorino U; de Braud FG; Vernieri C; Simbolo M; Bria E; Scarpa A; Indraccolo S; Broggini M; Sozzi G; Garassino MC
J Thorac Oncol; 2018 Nov; 13(11):1692-1704. PubMed ID: 30149143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
